Immunotherapy of cancer is a part of biotherapy

References

[1] Leach DR,Allison JP.Enhancement of antitumor immunity by CTLA-4 blockade..Science1996;271:1734-6

[2] Oldham RK.Cancer biotherapy: more than immunotherapy..Cancer Biother Radiopharm2017;32:111-4

[3] Cong L,Cox D,Barretto R,Hsu PD,Jiang W,Zhang F.Multiplex genome engineering using CRISPER/Cas systems..Science2013;339:819-23 PMCID:PMC3795411

[4] Currie GA.Eighty years of immunotherapy: a review of immunological methods used for treatment of human cancer..Brit J Cancer2012;26:141-53

[5] Markus MY.Tolerance and cancer: mechanisms of tumor envision and strategies for breaking tolerance..J Clin Oncol2004;22:1136-51

[6] Von Epps HL.Rules of engagement: the discovery of MHC restriction..J Exp Med2005;201:665 PMCID:PMC2212838

[7] Chin LT,Chen HM,Liao SK.Immune intervention with monoclonal antibodies targeting to CD152 (CTLA-4) for autoimmune and malignant diseases..Chang Gung Med J2008;31:1-15

[8] Couzin-Frankel J.Breakthrough of the year 2013. Cancer immunotherapy..Science2013;342:1432-3

[9] Chen DS.Element of cancer immunity and cancer-immune set point..Nature2017;541:321-30

[10] Chen M,Xiao W,Tian Z.NK cell-based immunotherapy for malignant diseases..Cell Mol Immunol2013;10:230-52 PMCID:PMC4076738

[11] Rosenberg SA,Muul LM,Chang AE,Matory YL,Shilone E,Sepp CA.Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukine-2 to patients with metastatic cancer..N Eng J Med1985;313:1485-92

[12] West WH,Yanelli JR,Orr DW,Oldham RK.Constant-infusion recombinant interleukine-2 in adoptive immunotherapy of advanced cancer..N Eng J Med1987;316:898-905

[13] Schmidt-Wolf IG,Kiem HP,Weissman IL.Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity..J Exp Med1991;174:139-49

[14] Rosenberg SA,Aebersold PM,Topalian SL,Simon P,Yang JC,Simpson C,Bock S,Wei JP.Use of tumor-infiltrating lymphocytes and interleukin 2 in the immunotherapy of patients with metastatic melanoma..N Eng J Med1988;319:1676-80

[15] Albert ML,Bhardwaj N.Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs..Nature1998;392:86-9

[16] Tarte K.Dendritic cell-based vaccine: a promising approach for cancer immunotherapy..Leukemia1999;13:653-63

[17] Fisher JP,Yan M,Anderson J.γδT cells for cancer immunotherapy: a systemic review of clinical trials..Oncoimmunology2014;3:e27572 PMCID:PMC3984269

[18] Imai C,Campana D.Gnetic modification of primary natural killer cells overcome inhibitory signals and induces specific killing leukemic cells..Blood2005;106:376-83 PMCID:PMC1895123

[19] Chacon JA,Sarnail AA.Contiuous 4-1BB co-stimulatoru signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy..Oncoimmunology2013;2:e25581 PMCID:PMC3850170

[20] Rosenberg SA.Adoptive cell transfer as personalized immunotherapy..Science2015;348:62-8

[21] Chmielewski M,Abken A.Antigen-specific T cell activation independent of MHC: chimeric antigen receptor redirected T cells..Front Immunol2013;4:371 PMCID:PMC3822734

[22] Ferrone S.Loss of HLA class I antigens by melanomas: molecular mechanisms, functional significanc and clinical relevance..Immunol Today1995;16:487-94

[23] Garcia-Lora A,Garrdo F.MHC class I antigens, immune surveillance, and tumor immune escape..J Cell Physiol2003;196:345-55

[24] Muller T,Maki G,Schimpf A,Tonn T.Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcome NK-resistance of lymphoma and leukemia cells..Cancer Immunol Immunother2008;57:411-23

[25] Cho FN,Shu CW,Liao SK,Yu MS,Hong YC,Chang YH.Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosis..PLoS One2014;9:e109352 PMCID:PMC4196898

[26] Hsieh CH,Chang CC,Chuang KL,Pang ST,Ferrone S.Total HLA class I loss in a sarcomatoid renal cell carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta 2 microglobulin genes..Cancer Imminol Immunother2009;58:395-408 PMCID:PMC2793116

[27] Kolher G.Continuous cultures of fused cells secreting antibody of predefined specificity..Nature1975;256:495-7

[28] Chen HC,Bridgeman JS,Jarry U,Piggott L,Li J,Herrmann T,Gallimore AM,Scotet E,Eberl M.Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8⁺ T cells..Immunol Cell Biol2017;95:620-9 PMCID:PMC5550559

[29] Vesely MD,Shreiber RD.Natural innate and adaptive immunity to cancer..Annu Rev Immunol2001;29:235-71

[30] Oldham RK,Ogden JR.Individually specified drug immunoconjugatein cancer treatment..In: Ceriani RL, editor. Breast Cancer Immunodiagnosis and Immunotherapy.1989;New YorkSpringer Science/Business Media219-30

[31] Muller A,Soto H,Cartron D,McClanahan T,Yuan W,Barrera JL,Verastegui E.Involvement of chemokine receptors in breast cancer metastasis..Nature2001;410:50-6

[32] Herman PC,Herrler T,Ellwart JW,Bruns CJ.Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer..Cell Stem Cell2007;1:313-23

[33] Chen HC,Liu YC,Kang CC,Yeh CT,Liao SK.Induction of metastatic cancer stem cells from the NK/LAK-resistant floating, but not adherent, subset of the UP-LN1 carcinoma cell line by IFN-γ..Lab Invest2010;91:1502-13

[34] Ting LL,Hsieh CH,Pang ST.Withaferin-A targeting both cancer stem cells and metastatic cancer stem cells in the UP-LN1 carcinoma cell model..J Cancer Metastasis Treat2016;2:29-40

[35] Hsieh CH,Wu-Chou YH,Chuang CK.Differential expression of CD44 and CD24 markers discriminates the epithelioid from the fibroblastoid subset in a sarcomatoid renal cell carcinoma cell line: suggestive evidence of the existence of cancer stem cells in both subsets with sorted cells..Oncotarget2016;8:15593-609

[36] Ahmed N,Kew Y,Powell S,Grossman PG,Gottschalk S.HER2-specific T cells target primary glioblasoma stem cells and induce regression of autologous experimental tumors..Clin Cancer Res2010;16:474-85 PMCID:PMC3682507

[37] Mao G,Sengupter S.Updates on chimeric antigen receptor-mediated glioblastoma immunotherapy..Rhode Island Med J2017;100:39-42

[38] Grossenbacker SK,Murphy WJ.Natural killer cell immunotherapy to target stem-like tumor cells..J Immuno Ther Cancer2016;4:19 PMCID:PMC4835831

[39] Wei F,Xie RY,Wang HY,Chen L,Lin XL,Yang S,Chen Y,Zhou HR,Chen YS,Yao KT.Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition..Oncotarget2015;6:35023-39 PMCID:PMC4741506

[40] Lee TC.Withaferin-A - a natural anticancer agent with pleiotropic mechanisms of action..Int J Mol Sci2016;17:290 PMCID:PMC4813154

[41] Sounni NE.Targeting the tumor microenvironment for cancer therapy..Clin Chem2013;59:85-93

[42] Stambrook PJ,Farzaneh F.Cancer immunotherapy: whence and whither..Mol Cancer Res2017;15:635-50 PMCID:PMC5457704

[43] Iwai Y,Chamato K.Cancer immunotherpies targeting the PD1 signaling pathway..J Biomed Sci2017;24:26 PMCID:PMC5381059

[44] Greelan BC.Update on immune checkpoint inhibitors in lung cancers..Cancer Cont2014;25:80-9

[45] Ott PA,Keskin D,Sun H,Zhang W,Giobbie-Hurder A,Chen C,Carter TA,Lieb DJ,Gjini E,Lane WJ,Nellalappan K,Daley H,Buchbinder EI,Harden M,Garbriel S,Barden M,Getz G,Neubergt D,Lander ES,Hacohen N.An immunogenic personal neoantigen vaccine for patients with melanoma..Nature2017;542:217-21 PMCID:PMC5577644

[46] Sahin U,Miller M,Simin P,Bukuri V,Luxemburger U,Omokoko T,Albrecht C,Andreas N,Buck J,Schreeb KH,Ortseifer I,Godehardt E,Rae R,Tolliver C,Martic G,Sorn P,Ciesla J,Bruck AK,Zillgen M,Kaesmann B,Bolte S,Kreiter S,Bolte S,Kreiter S,Gebhardt C,Holler C,Huber C,Tureci O.Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer..Nature2017;547:222-6

[47] Oldham RK.Cancer and diabetes: are there similarities?.Cancer Biother Radipharm1997;12:1-3

[48] Oldham RK.The cure for cancer..J Biol Resp Modif1985;3:111-6

[49] Scarfo I.Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment..J Immuno Ther Cancer2017;5:28 PMCID:PMC5359946

[50] Alderton GK.Immunotherapy: engineered T cells for all..Nat Rev Cancer2017;17:206-7

[51] Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review. Available from: https://www.novartis.com/news/media-releases/novartis-announces-first-car-t-cell-therapy-blapediatric-and-young-adult. [Last accessed on 15 Jan 2018]

[52] Roots Analysis. T-Cell Immunotherapy Market (2nd Edition), 2017-2030. Available from: https://www.rootsanalysis.com/reports/view_document/t-cell-immunotherapy-market-2nd-edition-2017-2030/151.html. [Last accessed on 15 Jan 2018]